Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors.
Tyler M ParsonsDivision of Oncology, Department of Medicine, Washington University School of Medicine; St. Louis, MO, USA, 63110.
Aishwarya KrishnanDivision of Oncology, Department of Medicine, Washington University School of Medicine; St. Louis, MO, USA, 63110.ORCID 0000-0001-6191-5966
Infencia Xavier RajDivision of Oncology, Department of Medicine, Washington University School of Medicine; St. Louis, MO, USA, 63110.
Andrew L YoungDivision of Hematology, Department of Medicine, Washington University School of Medicine; St. Louis, MO, USA, 63110.
David R O'LearyDivision of Oncology, Department of Medicine, Washington University School of Medicine; St. Louis, MO, USA, 63110.ORCID 0000-0002-5757-5150
Jason ArandDivision of Oncology, Department of Medicine, Washington University School of Medicine; St. Louis, MO, USA, 63110.
Maggie CoxDivision of Hematology, Department of Medicine, Washington University School of Medicine; St. Louis, MO, USA, 63110.
Stephen T OhDivision of Hematology, Department of Medicine, Washington University School of Medicine; St. Louis, MO, USA, 63110.ORCID 0000-0002-8564-5400
Grant A ChallenDivision of Oncology, Department of Medicine, Washington University School of Medicine; St. Louis, MO, USA, 63110.ORCID 0000-0003-4669-8814
Funding
Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI TIMOTHY J. EBERLEIN · 2001 to 2026
$128.0M
PRE-AND POSTGRADUATE TRAINING IN MOLECULAR HEMATOLOGYT32HL007088 · NHLBI · WASHINGTON UNIVERSITY · PI Grant Anthony Challen, Stephen Oh · 1985 to 2026
$14.1M
DYSREGULATED NFKB PATHWAY SIGNALING IN MYELOPROLIFERATIVE NEOPLASMSR01HL134952 · NHLBI · WASHINGTON UNIVERSITY · PI Stephen Oh · 2018 to 2026
$3.9M
Inflammatory Stress Promotes Clonal Expansion of DNMT3A-mutant HSCsR01DK124883 · NIDDK · WASHINGTON UNIVERSITY · PI Grant Anthony Challen · 2020 to 2026
$2.5M
JAK/STAT signaling in the pathogenesis of DNMT3A mutant T-ALLR01CA236819 · NCI · WASHINGTON UNIVERSITY · PI CHALLEN, GRANT ANTHONY · 2020 to 2024
$1.8M
Functions of JARID2 in Normal and Neoplastic HematopoiesisR01HL147978 · NHLBI · WASHINGTON UNIVERSITY · PI CHALLEN, GRANT ANTHONY · 2019 to 2022
$1.6M
Impact of Clonal Hematopoiesis on Solid Tumor Development and Response to TherapyK99CA296777 · NCI · WASHINGTON UNIVERSITY · PI Tyler Matthew Parsons · 2025 to 2026
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Parallel Evolution of Leukemic Clones in Myeloproliferative Neoplasms. · full record | Socratic